Near-Patient Molecular Solutions Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The near-patient molecular solutions market is gaining considerable traction as healthcare shifts toward more accessible and rapid diagnostic tools. With advances in technology and growing demand for personalized and decentralized testing, this sector is positioned for substantial growth in the years ahead. Below is a detailed exploration of market size projections, key players, emerging trends, and the main segments driving this expansion.

Projected Market Growth and Size of the Near-Patient Molecular Solutions Market
The near-patient molecular solutions market is poised for significant growth, anticipated to reach $7.17 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.5% during the forecast period. Several factors contribute to this surge, including an increased emphasis on personalized medicine, a growing preference for remote and home-based testing options, continual technological advancements in compact molecular diagnostic platforms, broader infectious disease surveillance efforts, and integration within digital health ecosystems. Important market trends expected to dominate the coming years include wider adoption of point-of-care molecular testing devices, heightened demand for rapid infectious disease diagnostics, greater use of portable PCR technologies, expansion of decentralized diagnostic networks, and a sharpened focus on improving the accuracy of near-patient testing.

The near-patient molecular solutions market size has grown strongly in recent years. It will grow from $4.54 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to expansion of molecular diagnostic techniques, demand for rapid test turnaround times, decentralization of laboratory services, growth in outpatient diagnostic settings, adoption of portable diagnostic instruments.

Download a free sample of the near-patient molecular solutions market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30333&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Fueling the Near-Patient Molecular Solutions Market Growth
One of the primary drivers of growth in this market is the rising interest in personalized medicine, which demands quick and precise molecular diagnostic results close to the patient. This shift reduces dependency on centralized laboratories and supports timely clinical decision-making.
Additionally, the surge in demand for home and remote testing solutions is a major catalyst. Patients and healthcare providers increasingly seek convenient, reliable molecular tests that can be performed outside traditional healthcare settings, emphasizing the need for portable and user-friendly devices.

Prominent Companies Leading the Near-Patient Molecular Solutions Market
The near-patient molecular solutions space is shaped by a number of influential companies, including Bosch Healthcare Solutions GmbH, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., bioMérieux SA, Sysmex Corporation, QuidelOrtho Corporation, QIAGEN NV, DiaSorin SpA, OraSure Technologies Inc., Molbio Diagnostics Pvt Ltd, Cue Health Inc., Biocartis Group NV, Vela Diagnostics Pte Ltd, Co-Diagnostics Inc., Hyris Ltd, and Genedrive plc.

View the full near-patient molecular solutions market report:
https://www.thebusinessresearchcompany.com/report/global-near-patient-molecular-solutions-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Significant Acquisition Enhancing Roche's Position in Near-Patient Testing
In a strategic move during July 2024, Roche Holding AG acquired LumiraDx's point-of-care technology business for $353.5 million. This acquisition grants Roche access to LumiraDx's compact, multi-assay diagnostic platform, greatly enhancing its capabilities in decentralized and near-patient testing. It also broadens Roche's reach into primary care and community settings by enabling rapid and dependable diagnostic results outside traditional lab environments. LumiraDx Group Limited, based in the UK, is recognized for its innovative point-of-care diagnostics that integrate immunoassay, clinical chemistry, and emerging molecular testing technologies in a single portable instrument.

Emerging Technological Trends in the Near-Patient Molecular Solutions Market
A key trend gaining momentum is the incorporation of advanced molecular techniques such as isothermal nucleic acid amplification. This technology improves test efficiency, portability, and accuracy by amplifying nucleic acid sequences at a consistent temperature, avoiding the need for complex thermal cycling used in traditional PCR.
For example, in June 2023, Cue Health Inc., a US-based molecular diagnostics company, received FDA approval for its Cue COVID-19 Molecular Test. This device uses isothermal amplification to provide rapid, accurate detection of SARS-CoV-2 RNA for at-home and point-of-care testing. The system includes a single-use cartridge, a Bluetooth-enabled reader, and a mobile app that guides users through testing and delivers results in approximately 20 minutes, thereby enhancing access to precise molecular diagnostics and supporting timely health decisions outside conventional labs.

Core Market Segments Driving the Near-Patient Molecular Solutions Expansion
This market is segmented by product type, technology, and end user, each encompassing multiple detailed categories:
1) Product Type includes Infectious Diseases Testing Kits, Urinalysis Testing Kits, Tumor or Cancer Markers, Pregnancy and Fertility Kits, Hematology Testing Kits, Glucose Monitoring Kits, Drugs-of-Abuse Testing Kits, Coagulation Monitoring Kits, Cardiometabolic Monitoring Kits, and other specialized products.
2) Technology covers Polymerase Chain Reaction (PCR)-Based methods, Genetic Sequencing-Based approaches, Hybridization-Based techniques, and Microarray-Based platforms.
3) End-User segmentation includes Hospitals and Clinics, Ambulatory Care Centers, Research Laboratories, Home Care Settings, and others.

More detailed subcategories address specific testing kits such as Hepatitis, HIV, Influenza, COVID-19 within Infectious Diseases; Protein, Glucose, ket*one, and Nitrite tests in Urinalysis; Prostate-Specific Antigen and Carcinoembryonic Antigen kits in Tumor Markers; ovulation and early pregnancy tests; Complete Blood Count and Hemoglobin kits in Hematology; self-monitoring and continuous monitoring glucose kits; urine, saliva and hair drug testing kits; coagulation time tests; lipid profile kits within Cardiometabolic Monitoring; and other specialized diagnostic kits including allergy and thyroid function tests.

Global Market Distribution and Regional Growth Patterns
Currently, the near-patient molecular solutions market is expanding worldwide, with a focus on enhancing diagnostic accessibility across various healthcare environments. While specific regional data was not detailed here, global trends point toward increasing adoption in both developed and emerging markets, supported by the growing need for decentralized healthcare solutions and rapid diagnostics.

In summary, the near-patient molecular solutions market is set for robust growth, driven by technological innovations, shifting healthcare models favoring personalized and decentralized testing, and strong participation from leading industry players. These developments collectively promise to reshape molecular diagnostics and improve healthcare outcomes by bringing reliable testing closer to patients.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.